新闻

RapAdmin

This review paper critically examines the therapeutic potential of postbiotics (inanimate microorganisms and their bioactive components) for preventing and managing cognitive impairment. The authors outline how short chain fatty acids, cell wall fragments, and microbial peptides fortify the gut and blood-brain barriers, limiting the systemic translocation of inflammatory mediators. Preclinical evidence strongly suggests these non-viable formulations suppress neuroinflammation, mitigate oxidative stress, and restore synaptic plasticity, presenting a stable and potentially safer alternative to live probiotics. The evidence underneath it is thin: seven rodent experiments, all in male animals, most using chemically induced memory loss, and no human cognitive trial is presented.

The central nervous system was once considered a pristine and isolated environment. That perspective is rapidly changing. Emerging evidence highlights a constant communication network linking the bacteria in the human digestive tract directly to the brain. When this communication breaks down, it accelerates cognitive decline and neurodegenerative diseases. While much attention has been placed on using live bacteria to fix this gut-brain communication, a new review shifts the focus to postbiotics. These are dead bacteria and the chemical byproducts they leave behind.

Live bacteria are fragile. They must survive the harsh acidic environment of the stomach and successfully compete with existing gut flora to provide any biological benefit. Postbiotics bypass these biological hurdles completely. Because they are inanimate, they are highly stable, easier to dose accurately, and carry a lower risk of causing unexpected infections in vulnerable patients.

The big idea presented by the researchers is that you do not need live bacteria to secure the neurological benefits of a healthy microbiome. The structural fragments of dead bacteria, alongside their fermented waste products like short chain fatty acids, are entirely sufficient to trigger profound protective responses across the gut-brain axis.

The cascade begins in the intestine. Age, poor diet, and chronic stress degrade the protective lining of the gut. This structural failure allows harmful bacterial toxins to leak into the bloodstream. These toxins travel to the blood-brain barrier, a specialized filter designed to protect the brain from peripheral immune threats. Chronic exposure to these circulating toxins degrades the blood-brain barrier. Once the barrier is compromised, inflammatory signals flood the brain, activating specialized immune cells called microglia. When microglia remain in a state of chronic alarm, they begin to damage synapses, disrupt energy production in mitochondria, and ultimately kill healthy neurons.

Postbiotics interrupt this destructive cycle at multiple distinct checkpoints. First, bacterial fragments and fatty acids bind to receptors in the gut lining, signaling the tissue to repair tight junctions and stop the initial leak of toxins. Second, when short chain fatty acids enter the bloodstream and reach the brain, they act as epigenetic modulators. They inhibit specific enzymes, allowing DNA to unspool and increase the production of proteins that strengthen the blood-brain barrier. Finally, these microbial molecules directly dampen the alarm systems inside the brain. They switch microglia from an active and destructive state back to a resting and protective state.

The implications for healthy aging are substantial. If postbiotics can reliably seal the gut, stabilize the blood-brain barrier, and quiet neurological inflammation, they represent a highly scalable intervention for delaying cognitive impairment. However, the current evidence relies heavily on laboratory rodents. The specific molecular signatures of dead bacteria that provide these benefits have not been fully isolated, and the exact dosages required to achieve meaningful results in humans remain completely unmapped.

Actionable Insights

For individuals interested in optimizing cognitive longevity, this research points toward a practical shift from focusing solely on live probiotics to supporting the internal production of postbiotics. Postbiotics, such as short chain fatty acids, are naturally generated when gut bacteria ferment dietary fiber. A highly actionable strategy is to consistently consume diverse, fiber rich plant foods, which acts as the raw material for your existing microbiome to manufacture these brain protecting molecules. Additionally, fermented foods and specific heat killed bacterial supplements may offer a more stable, predictable way to fortify the gut barrier compared to live probiotic capsules, which often die before reaching the lower intestine.

Despite these promising biological mechanisms, it is critical to evaluate the real world magnitude of the intervention. A rigorous review of the provided data reveals a complete omission of quantitative baseline and outcome metrics in this research paper. The source material provides only directional indicators of physiological changes. Consumers should remain cautious and view postbiotics as a foundational health practice rather than a proven cure for cognitive decline.

Context/Source

相关阅读:

RapAdmin

A review from HHMI’s Janelia Research Campus argues that lysosomes, mitochondria, and the endoplasmic reticulum (ER) regulate aging as signaling hubs, in addition to their metabolic roles. They communicate with the nucleus, with each other through physical contact sites, with distant tissues through secreted factors, with gut bacteria, and, in worms, with future generations through epigenetic marks. The authors propose that dietary restriction, fasting, rapamycin, metformin, and exercise converge on these same circuits, chiefly the mTORC1 and AMPK switch on the lysosomal surface.

For most of the last century, biologists treated the compartments inside our cells as specialist workshops. Mitochondria made energy, lysosomes took out the trash, and the endoplasmic reticulum folded proteins. A new review from Meng Wang’s laboratory at the Howard Hughes Medical Institute’s Janelia Research Campus argues that this picture is too tidy. Aging, it says, is better understood as a breakdown in how these compartments talk to one another and to the nucleus.

The review, published in Nature Cell Biology, pulls together about 200 studies. Its central claim is that organelles are signaling hubs as well as metabolic machines. The lysosome is the clearest example. Its surface is where two master nutrient sensors, mTORC1 and AMPK, are switched on, apparently competing for the same docking platform. When lysosomes lose acidity or spring leaks with age, the damage goes beyond failed waste disposal. In yeast, a less acidic lysosome starves mitochondria of iron and cripples them. In worms, boosting fat breakdown inside the lysosome sends lipid messengers to the nucleus and to neurons, and the animals live longer.

Mitochondria tell a similar story. Mild mitochondrial stress, of the kind produced by slightly throttling the respiratory chain, triggers protective gene programs and extends lifespan in worms, flies and, in a few studies, mice. Metabolites from the mitochondrial energy cycle, such as alpha-ketoglutarate and citrate, double as raw material for the chemical tags that control which genes are active. The endoplasmic reticulum follows the same rule of moderation. A brief, mild stress response is protective, while a chronic one accompanies cancer, diabetes and neurodegeneration.

The most striking material concerns distance. Stress in a worm’s neurons can switch on mitochondrial defenses in its gut. Stressed mouse muscle releases the hormones GDF15 and FGF21, which alter fat, liver and brain metabolism. Gut bacteria produce compounds, including colanic acid and short-chain fatty acids, that reshape host mitochondria. Most surprising of all, worms that experience starvation or neuronal mitochondrial stress can pass a longevity benefit to descendants for several generations, through changes in histone packaging and mitochondrial DNA levels.

The authors then recast familiar interventions in this light. Dietary restriction, fasting, rapamycin, metformin and exercise all appear to act on the same lysosome and mitochondria circuits, mostly by turning mTORC1 down and AMPK up.

Readers should keep the evidence base in view. This is a narrative review with no new experiments and no pooled statistics. The bulk of the lifespan findings come from the nematode C. elegans, an animal that lives about three weeks, and a large share of the lysosomal work comes from the authors’ own laboratory. The transgenerational results have no demonstrated counterpart in mammals. Human evidence is limited to associations and short biomarker studies. The review also lists metformin as lifespan extending in mice without mentioning that a larger, multi-site mouse trial failed to confirm the effect.

What the paper offers is a map. It gives researchers a framework in which lysosomal acidity, membrane repair and the contact points between organelles become candidate drug targets. Whether fixing them slows human aging remains untested.

Actionable Insights

This paper tests nothing new in people, so it cannot tell you to add anything to your regimen. Its practical value is in showing which existing habits have the deepest mechanistic support.

Exercise is the strongest case. It is the only intervention in the review with consistent human data showing better mitochondrial function. Large observational studies outside this review link regular activity to roughly 20 to 30 percent lower death rates over follow-up.

For the compounds, the review gives no effect sizes. The original mouse studies it cites report modest numbers:

  • Metformin: about 6 percent longer average life in one study, roughly seven to eight extra weeks for a mouse.
  • Nicotinamide riboside: about 5 percent when started in old age.
  • Spermidine: about 10 percent.
  • Alpha-ketoglutarate: 10 to 17 percent, in females only.
  • Rapamycin: 9 to 26 percent depending on dose and timing.

Metformin and nicotinamide riboside both failed to extend lifespan in the larger NIA Interventions Testing Program.

Dose matters in both directions. The same stress pathways that protect when mildly activated cause harm when chronically active, and high-dose metformin shortened mouse lifespan by about 14 percent.

Human trials of urolithin A and nicotinamide riboside show changes in muscle biomarkers, with no evidence yet on lifespan.

Context and Source

  • Paywalled Paper: Organellar insights in ageing and longevity
  • Institution: HHMI Janelia Research Campus, Ashburn, Virginia
  • Country: USA
  • Journal: Nature Cell Biology, (published online 17 April 2026)
  • Impact evaluation: The impact score of this journal is 19.1 (Journal Impact Factor), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

University of Minnesota researchers, the same group behind the 2018 mouse study that made fisetin a popular supplement, now report that fisetin is a weak and poorly selective senolytic. They screened 38 natural flavonoids, built 35 synthetic analogs, and selected two leads: SR29384 (most selective) and SR31133 (most potent). In old mice, a short oral course of SR29384 lowered senescence and inflammation gene activity in several organs by roughly 30 to 70 percent, while fisetin at the same low dose did little. In fast-aging mice, the overall health score did not improve and only one symptom, ataxia, was consistently better.

Fisetin, the strawberry flavonoid sold widely as a senolytic supplement, has a problem that its own champions now acknowledge: it is not very good at the job. A team led by Paul Robbins and Laura Niedernhofer at the University of Minnesota reports in Aging Cell that fisetin is a weak killer of senescent cells, and describes two synthetic replacements designed to do better.

Senescent cells are damaged cells that stop dividing but refuse to die. They build up with age and leak inflammatory signals that harm neighboring tissue. Senolytics are drugs meant to remove them while sparing healthy cells.

The team first tested 38 natural flavonoids on senescent mouse cells. Fisetin needed about 23 micromolar to kill half of them, and it was only 1.5 times more toxic to senescent cells than to healthy ones. Luteolin, found in celery and parsley, did slightly better. Using those results as a map of which parts of the molecule matter, chemists then made 35 new compounds. Two stood out. SR29384 was about three times more potent than fisetin and nearly nine times more toxic to senescent cells than to normal ones. SR31133 was 27 times more potent, but with a much narrower margin between killing senescent cells and killing healthy ones.

In 28-month-old mice, roughly equivalent to people in their late seventies, five daily oral doses of SR29384 cut kidney activity of p16, a standard senescence gene, by about 65 percent and the inflammatory gene Il6 by about 70 percent. Fisetin at the same dose did almost nothing. That comparison flatters the new compounds, because fisetin is normally given to mice at five times that dose.

The harder test came in mice engineered to age rapidly. After five weeks of treatment, senescence and inflammation genes fell by 30 to 55 percent in kidney, liver and lung. But the overall health score, which the authors name as the primary outcome, did not differ from untreated mice at any time point. Only ataxia, a loss of coordination, was reliably better late in treatment.

How the compounds work is also unsettled. Computer modeling and enzyme tests point to two proteins: PARP1, which helps repair DNA, and CDK2, which controls cell division. Yet the concentrations needed to block those enzymes were mostly higher than the concentrations that killed senescent cells, which suggests something else is contributing. The expected target, BCL-xL, was ruled out.

Much is missing. Nobody measured how much drug reached the blood or tissues, whether it caused harm, or whether senescent cells were physically removed as opposed to quieted. Two senior authors co-founded a company developing senolytics, and several authors hold a patent filing on these molecules.

The result is a credible chemistry starting point and a notable downgrade of fisetin by the people who put it on the map. It is not yet evidence that the health of an aging animal improves.

Insights

  1. Nothing here can be taken or bought. SR29384 and SR31133 are patented research chemicals with no human, safety or blood-level data.
  2. The paper weakens the case for fisetin supplements. In the authors’ own cells, fisetin was only 1.5 times more toxic to senescent cells than to healthy ones, and at 20 mg/kg in old mice it changed senescence genes by roughly 0 to 10 percent. Earlier positive mouse work used 100 mg/kg, which scales to about 570 mg for a 70 kg adult, and fisetin is poorly absorbed.
  3. Luteolin beat fisetin in the dish (14 versus 23 micromolar), but those concentrations are far above what oral supplements are known to reach in blood. This is not a reason to switch.
  4. Size of benefit for the lead compound: senescence and inflammation genes dropped 30 to 70 percent in mouse organs. That is a very large shift in statistical terms (the average treated mouse scored lower than about 93 percent of untreated mice), but it is based on 4 to 6 animals per group, so the true effect could be far smaller. The whole-animal health score did not improve.
  5. One likely target, PARP1, is a DNA repair enzyme. Chronic blockade in healthy people carries plausible risk.

Context and Source

  • Open Access Paper: Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan, Published 06 October 2026.
  • Institutions: Masonic Institute on the Biology of Aging and Metabolism, University of Minnesota (lead); University of Georgia College of Pharmacy; Herbert Wertheim UF Scripps Institute; University G. d’Annunzio of Chieti-Pescara
  • Country: USA, with one Italian affiliation
  • Journal: Aging Cell (Wiley, for the Anatomical Society), 2026, volume 25, e70736
  • Impact evaluation: The impact score of this journal is 7.7, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal. Within aging biology specifically it is a top-tier specialty venue.

RapAdmin

This invited review by Tony Wyss-Coray and Eric Topol surveys the tools that estimate biological age, from DNA methylation clocks to newer blood protein clocks that assign separate ages to individual organs and cell types. Its main argument is that aging is nonlinear, differs widely between people, and runs at different speeds in different organs of the same person. Clocks reliably sort large groups by risk of death and disease, with brain and immune system age standing out as the strongest predictors. The authors state plainly that the clocks are not validated for individual clinical use, that causality is unproven, and that consumer tests are unstandardized.

Your birth certificate is a poor guide to how old your body is. That is the central message of a new review in Nature Medicine by Stanford neuroscientist Tony Wyss-Coray and Scripps cardiologist Eric Topol. They conclude that biological aging clocks are scientifically impressive but not yet fit for the clinic.

Aging clocks are statistical models that estimate biological age from molecular data. The first, built in 2013, read chemical tags on DNA. Later versions were trained to predict death and disease instead of birthdays, and a third type estimates the speed of aging. The newest generation reads thousands of proteins in a small blood sample. It assigns a separate age to the brain, heart, liver, kidneys, arteries and immune system, and more recently to about 40 individual cell types.

Two ideas run through the review. The first is that aging is not a steady slope. Pooling seven studies, the authors describe waves of molecular change clustering around ages 33, 60, 69 and 78. The second is that organs within one person age at different speeds. In a British cohort of about 1,800 people born in 1946, organ ages measured at 63 spanned roughly a decade. People whose organs ranked in the oldest tenth died at about 1.5 to 3 times the rate of everyone else, and those with three or more such organs fared worst.

The brain and immune system stand out. In UK Biobank data, people with youthful brain or immune profiles survived longest. An old-looking brain was linked to a threefold higher rate of Alzheimer’s disease, regardless of APOE genotype. At the cell level, people whose astrocytes looked oldest developed Alzheimer’s about five times as often as average.

The authors are frank about what is missing. Almost all of the evidence comes from single blood draws in large population studies, many drawing on the UK Biobank, which lacks diversity. That shows clocks can sort groups by risk. It does not show that a reading tells one person anything reliable, or that pushing a clock number down prevents disease. Exercise shifts epigenetic clocks favorably. Omega-3, vitamin D, a daily multivitamin and the shingles vaccine produce smaller shifts, with unknown consequences for lifespan.

The review is blunt about consumer tests. Products costing 300 to 500 US dollars are sold without regulatory approval or standardization, and one person can get markedly different results from different tests.

The practical test of the idea is now underway. A randomized trial (NCT07646054) will assign people at high risk of Alzheimer’s to intensive lifestyle coaching or educational materials. It will track a blood marker, p-tau217, and the proteomic brain clock. The authors concede that both are stand-ins that still need validation against actual disease.

The big idea is that clocks could move medicine from treating disease to preventing it, by showing who is at risk and roughly when. For now that remains a research agenda.

Actionable Insights

  1. Do not buy a consumer aging test to guide decisions. The review says individual-level usefulness is unproven and repeat tests can disagree.
  2. The clocks point back to familiar habits. In the 1946 British cohort, sustained physical activity was linked to younger organs; smoking and adolescent overweight were linked to older ones. These are associations, not proof of cause.
  3. Exercise has the most consistent clock evidence, with larger shifts at higher activity levels. The review gives no numbers.
  4. Keep the risk numbers in proportion. Over 15 years, about 6.5 of every 100 people with the oldest-looking astrocytes developed Alzheimer’s, against 1.5 of every 100 average people. That is about four times the risk, but 93 of 100 in the worst group stayed free of the disease.
  5. For multi-organ aging, about 66 percent of people with 20 or more extremely aged cell types died within 15 years, against about 10 percent of normal agers. That group was under 1 percent of the population.

Context and Source

  • Paywalled Paper: Biological aging clocks in health and disease
  • Authors: Tony Wyss-Coray and Eric J. Topol
  • Journal: Nature Medicine, published online 9 July 2026
  • Institutions: Stanford University School of Medicine (Department of Neurology, Knight Initiative for Brain Resilience, Wu Tsai Neurosciences Institute) and Scripps Research Translational Institute
  • Country: USA
  • Impact evaluation: The impact score of this journal is 52.5, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is an Elite impact journal.

RapAdmin

A Perspective in Science argues that the postmenopausal ovary, long dismissed as a spent organ, stays biologically active for decades. It continues to secrete hormones, mainly testosterone, and in mice, monkeys, and some human samples it accumulates immune cells and senescent stromal cells with a secretory profile. The authors propose that the aged ovary could feed whole-body “inflammaging” in older women.

For most of medical history, the ovary after menopause has been treated as leftover tissue. Textbooks have called it senile, a shriveled husk. Michael Stout of the Oklahoma Medical Research Foundation and Francesca Duncan of Northwestern University and the Buck Institute argue that this picture is wrong, and that the error matters because women now spend roughly a third of their lives after menopause.

The ovary does change at menopause. It loses its follicles, shrinks by about 30 percent, and becomes dominated by stroma, the connective tissue scaffold, along with fibrosis and thickened blood vessels. But it does not go silent. Blood sampled directly from the ovarian vein shows the postmenopausal ovary still releases testosterone, plus smaller amounts of androstenedione, estradiol, estrone, and progesterone. Its stromal cells still carry receptors for the pituitary hormones LH and FSH, and still respond to them.

The newer and more provocative claim concerns inflammation. In mice past reproductive age, the ovary fills progressively with T cells, macrophages, and multinucleated giant cells, and its gene activity shifts from reproductive programs toward immune activation. In aging monkeys, spatial mapping finds inflammatory pockets in the stroma that look like sources of senescence signals. In women aged 50 to 75, a proteomic study still at the preprint stage reports that older ovaries express more proteins tied to complement activation, senescence, and tissue remodeling. When postmenopausal human ovarian tissue is exposed in culture to doxorubicin, a drug that induces senescence, its secretions resemble those of naturally aged ovaries.

Put together, the authors suggest the old ovary may behave something like fat tissue, which was once considered inert storage and is now recognized as an endocrine organ that shapes disease risk. If the ovary leaks inflammatory factors into the circulation, it could contribute to cardiovascular disease, neurodegeneration, muscle loss, and metabolic dysfunction.

The authors do not oversell this. They state that the idea is “only inferential.” One human cell atlas found few immune cells and few senescence markers in the postmenopausal ovary, contradicting the other datasets. Nobody has shown that ovary-derived inflammatory molecules reach meaningful concentrations in blood.

The obvious follow-up question is whether removing the ovaries after menopause would help. Here the evidence is thin and indirect. Removing ovaries before menopause clearly harms health, raising cardiovascular and all-cause mortality, but that reflects sudden hormone loss in younger women. A 2005 modeling study concluded that keeping the ovaries improved survival up to about age 65. A 2022 update found no survival penalty from removing them at hysterectomy at age 50 or later. No penalty is not the same as a benefit, and the authors caution that ovarian androgens still support bone, libido, and metabolism.

The piece is a research agenda, not a result. Its value lies in the question it puts on the table.

Actionable Insights

The practical messages are about decisions women already face.

First, timing dominates. In the Nurses’ Health Study, 16.8 percent of women whose ovaries were removed at hysterectomy died over 28 years, against 13.3 percent who kept them. That is a 3.5 percentage point gap, and after adjusting for other risk factors, a 13 percent higher death rate. Among women under 50 who never took estrogen, the death rate was 41 percent higher, roughly one extra death for every eight surgeries over 35 years.

Second, estrogen therapy appears to offset most of that harm in younger women. In the 2022 model, 52.8 percent of women who lost their ovaries before 50 without estrogen survived to 80, against 63.5 percent who kept them, an 11-point gap that disappeared with estrogen use.

Third, at 50 or older the modeled difference is negligible: 66.9 percent versus 66.4 percent surviving to 80. That is half a percentage point, well inside the margin of error.

Fourth, nothing here supports removing healthy ovaries to reduce inflammation.

Context and Source

  • Paywalled Paper: “Does the postmenopausal ovary still matter?”
  • Institutions: Oklahoma Medical Research Foundation and Oklahoma City VA Medical Center; Feinberg School of Medicine, Northwestern University; Buck Institute for Research on Aging
  • Country: USA
  • Journal: Science, 1 October 2026.
  • Impact evaluation: The impact score of this journal is 45.8, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is an Elite impact journal.

RapAdmin

Researchers at Soochow University put 18-month-old male mice through eight weeks of moderate treadmill running, then injected them with bacterial endotoxin (LPS) to trigger brain inflammation. Sedentary mice given LPS performed worse on a spatial memory test and showed more hippocampal inflammation, oxidative damage, and cell-death signaling, along with weaker mitochondrial respiration. Mice that had exercised beforehand performed about as well as uninjected controls, and their hippocampal mitochondria looked healthier on nearly every marker measured.

Older adults often come out of an infection mentally foggier than they went in. A new mouse study asks whether being physically fit beforehand can blunt that hit, and whether mitochondria are part of the explanation.

The team took 32 male mice aged 18 months, old by mouse standards, and split them into four groups of eight. Two groups ran on a treadmill for 40 minutes a day, five days a week, for eight weeks. Two stayed sedentary. A day after the final session, one sedentary group and one trained group received a single injection of lipopolysaccharide, a bacterial cell-wall component that provokes a strong inflammatory response. Three hours later, all mice began six days of testing in the Morris water maze, where they must remember the location of a hidden platform.

Sedentary mice given LPS did poorly. On the final memory test they spent about 27 percent of their time in the correct quadrant of the pool, which is close to what random swimming would produce, compared with about 37 percent for untreated controls. Trained mice given the same injection scored about 38 percent, the same as healthy controls.

The hippocampus, the brain region central to this kind of memory, showed the same pattern. In sedentary LPS mice, inflammatory proteins rose and microglia, the brain’s immune cells, shifted into their activated shape. Markers of oxidative damage and programmed cell death went up, while levels of BDNF, a protein that supports learning, fell by roughly 40 percent. Prior exercise prevented most of these changes.

The authors then looked at mitochondria. Using high-resolution respirometry, they found that hippocampal tissue from sedentary LPS mice had about 30 percent lower maximal respiratory capacity. In trained mice the capacity was preserved, and in fact sat slightly above control levels. Protein markers suggested that exercise also kept the cell’s cleanup machinery (autophagy) running, kept the energy sensor AMPK active, and held the balance between mitochondrial fission and fusion steady.

The authors’ big idea is that mitochondrial fitness acts as a buffer. A brain whose mitochondria are in good order may absorb an inflammatory challenge without tipping into a self-reinforcing loop of oxidative stress, inflammation, and cell death.

That idea is plausible but not shown here. The study never tests whether the mitochondrial changes cause the memory protection. Nobody blocked autophagy or AMPK to see whether the benefit disappeared. Everything was measured at one time point, about eight days after the injection, in whole tissue that mixes neurons, microglia, and astrocytes. Most molecular results come from three animals per group.

There are other constraints. All the exercise happened before the insult, so this is evidence about resilience, not recovery. The mice were all male. The treadmill running was forced. And the claim to be “the first evidence” of this effect is hard to square with earlier work in aged rats showing that wheel running protected against infection-induced memory loss.

So the result adds mechanistic detail to a familiar message. Regular aerobic exercise appears to leave the aging brain better equipped to ride out an inflammatory episode, and healthier mitochondria travel with that protection. Whether they drive it is still an open question.

Actionable Insights

The practical message is one you have heard before: build an aerobic base before you need it. In this study the exercise was done before the inflammatory insult, so the finding concerns preparedness, not rescue once illness strikes.

The dose was modest: 40 minutes of moderate effort, five days a week, for eight weeks. That is 200 minutes weekly, close to standard human guidelines of 150 to 300 minutes.

How big was the effect? Sedentary mice given endotoxin spent about 27 percent of their time searching in the right place, versus 37 percent for healthy controls. Exercised mice given endotoxin scored about 38 percent. In plain terms, the deficit was fully erased. Expressed as a standardized effect size (Cohen’s d, which counts how many “typical spreads” separate two groups), the benefit was roughly 2 to 3. Anything above 0.8 is conventionally called large.

Do not expect that in people. Tiny, uniform groups of lab mice routinely produce inflated effect sizes. Human trials of exercise for cognition in adults over 50 report benefits near 0.3, which is real but small.

Context/Source

RapAdmin

This narrative review argues that postbiotics (killed microbes and their components) could slow cognitive decline by acting along the gut-brain axis. The proposed chain runs from a tighter gut barrier to less inflammatory leakage into the blood, a sturdier blood-brain barrier, calmer microglia, healthier mitochondria and better-preserved synapses. The supporting evidence is seven rodent studies, all in males, plus cell-culture work. The review tabulates no human trials, and the authors themselves conclude that postbiotics are experimental and unproven for cognitive impairment.

Probiotics have a problem: they are alive. Live bacteria must survive manufacturing, shelf storage and stomach acid, and they carry a small infection risk in frail people. Postbiotics sidestep this. They are preparations of heat-killed microbes or their fragments which, according to a new review in Ageing Research Reviews, may still send useful signals to the body after death.

The review, from a team at ISF College of Pharmacy in Punjab, India, asks whether those signals reach the brain. The authors lay out a relay. Dead bacterial cell walls and associated molecules interact with immune receptors in the gut lining. This may tighten the junctions between gut cells and reduce the leakage of bacterial toxins such as lipopolysaccharide into the bloodstream. With fewer inflammatory signals circulating, the blood-brain barrier holds up better, the brain’s immune cells stay calmer, mitochondria produce less oxidative damage, and synapses keep working.

It is a tidy story, and each link has some laboratory support. In rats given a chemical cocktail that mimics aspects of Alzheimer’s disease, heat-killed Bifidobacterium animalis improved maze performance and reduced amyloid build-up over 13 weeks. In mice bred to age quickly, Lacticaseibacillus paracasei improved memory and raised hippocampal dopamine and serotonin. A heat-treated Limosilactobacillus fermentum product protected mice from drug-induced amnesia.

The weakness is the size and quality of that evidence base. The review tabulates seven animal studies. Every one used male rodents. None of the group sizes or the magnitude of benefit are reported in the review, only the direction of change. The models rely on chemical injury or accelerated-aging strains that have a poor record of predicting which treatments work in human dementia. No human trial data are presented.

There is also a definitional tangle. The authors adopt the official consensus definition, under which purified metabolites such as butyrate are not postbiotics. Yet most of the molecular detail in the review, from histone deacetylase inhibition to free fatty acid receptor signaling, comes from studies of exactly those purified short-chain fatty acids. The mechanism described and the product being promoted are not the same thing.

The big idea is plausible and worth testing, since a stable, non-living oral product that reduces gut-derived inflammation would be attractive for older adults. For now, the claim that it protects human cognition is a hypothesis built on rodent mazes.

Actionable Insights

There is no validated human dose, product or protocol in this paper. Anyone buying a “postbiotic for brain health” is running a personal experiment.

Effect size: none can be calculated. The review reports only the direction of results (for example, “improved spatial memory”) without group means, variability or sample sizes. In plain terms, we know the treated animals did better, but not whether they did 5 percent better or 50 percent better. The human effect size is currently unknown, and the default assumption should be zero until trials say otherwise.

Practical points:

  • Animal doses were roughly 100 million to 1 billion killed cells per kilogram or per day, for 2 to 18 weeks. These do not translate reliably to human doses.
  • The best-supported mechanism in the paper involves short-chain fatty acids, which your own gut bacteria make from dietary fiber. Eating adequate fiber and fermented foods is a lower-cost way to act on the same biology, although it is also unproven for cognition.
  • Heat-killed bacterial products are probably low risk for healthy adults, but long-term safety data in cognitively impaired people do not exist.
  • Postbiotics are not a substitute for prescribed dementia medications.
  • Strain matters. Results from one strain cannot be assumed for another.

Context/Source

RapAdmin

A new systematic review in Gut Microbes pulls together 91 studies on how molecules made by gut bacteria affect mitochondria. It covers ten classes of compounds, from butyrate and urolithin A to uremic toxins and bacterial endotoxin. The authors conclude that these chemically unrelated molecules act on the same few control points: the electron transport chain, oxidative stress handling, the creation of new mitochondria, and the removal of damaged ones. Only four compounds (butyrate, propionate, indoxyl sulfate and lipopolysaccharide) earned a “moderate” certainty rating, and that rating describes the direction of a lab effect, not a health benefit. Nearly all the evidence is from cells and rodents, often at doses far above what circulates in human blood.

The idea that gut microbes shape human health has been attached to almost every disease. This review asks a narrower question: when a bacterial product reaches a human cell, what does it do to the mitochondria?

Richard Frye and Daniel Rossignol searched three databases through March 2026 and screened 1,412 records down to 91 studies. They sorted the evidence into ten classes: short-chain fatty acids, secondary bile acids, tryptophan derivatives, uremic toxins and TMAO, hydrogen sulfide, lipopolysaccharide, B vitamins, polyphenol metabolites such as urolithin A, D-lactate, and polyamines such as spermidine.

Their big idea is convergence. Molecules that have nothing in common chemically keep landing on the same mitochondrial machinery. A regulator called PGC-1alpha, which controls the building of new mitochondria, appears again and again. Helpful compounds such as butyrate tend to switch it on. Harmful ones such as indoxyl sulfate, which accumulates in kidney disease, tend to shut it down.

The second theme is dose. Many of these molecules help at low concentrations and harm at high ones. Hydrogen sulfide feeds electrons into the respiratory chain below roughly 20 micromolar and blocks it, cyanide-style, above that. Propionate is a useful fuel at normal levels and jams mitochondrial metabolism when it builds up. Indole-3-propionic acid, often promoted as a beneficial metabolite, raised cellular respiration by about a fifth at a low dose and cut it by a similar amount at a high one.

The reviewers are unusually frank about the weakness of the evidence. Fifty-seven of the 91 studies used cultured cells and 28 used animals. They count only seven as human studies, and most of those measured gene activity or blood markers, not mitochondrial function. No compound achieved a “high” certainty rating. Four reached “moderate”: butyrate (generally beneficial), propionate (harmful at high doses), indoxyl sulfate (harmful) and lipopolysaccharide (mostly harmful).

Urolithin A, which is marketed on the strength of its ability to trigger mitophagy, was rated “low”. The mitophagy evidence comes from worms, mice and muscle cells. The human trial showed safety and shifts in blood and gene markers, but it never measured mitophagy itself.

The concentration problem may matter most. Butyrate experiments typically use 1 to 10 millimolar, which is realistic for the inside of the colon. Human blood contains less than 1 micromolar. Spermidine studies use doses up to 1,000 times normal plasma levels. A cell in the heart or brain never sees what a cell in a dish is given.

The result is a map of plausible mechanisms. The authors say so directly, calling the findings hypothesis-generating and the proposed therapies speculative.

Actionable Insights

Nothing in this paper proves that changing a gut metabolite improves human health or lifespan. With that stated, the practical reading is as follows.

  • Fiber: Fermentable fiber is the best-supported lever, because it feeds butyrate production where butyrate acts, in the colon. Colon cells from germ-free mice had 56 percent less ATP, and butyrate restored energy production to about 70 percent of normal. That is a large effect, but it is in mouse gut cells.
  • Butyrate pills: Oral butyrate is unlikely to reproduce the lab findings elsewhere in the body. Blood levels sit under 1 micromolar, more than 1,000 times below test doses.
  • Urolithin A: Only 30 to 40 percent of people make it from pomegranate, berries or walnuts. Supplements changed blood markers within 28 days, but no human study has confirmed mitophagy.
  • Nicotinamide riboside: A dose of 1,000 mg per day raised muscle mitochondrial DNA in a twin study, but only four twin pairs were compared against placebo.
  • Kidney function: Indoxyl sulfate ran 10 to 21 times higher in dialysis and end-stage patients and tracked with weaker muscle. Protecting kidney function matters more than any supplement here.

No standardized effect sizes (such as Cohen’s d) can be calculated, because the review reports no group means or variability.

Context and Source

RapAdmin

Researchers at Imperial College London gave 28 healthy, psychedelic-naive adults a 1 mg placebo dose of psilocybin, followed four weeks later by a 25 mg dose, with EEG during dosing and MRI before and one month after each session. The high dose sharply increased the irregularity (“entropy”) of brain electrical activity for several hours, and the size of that increase predicted next-day psychological insight and one-month gains in well-being. At one month, participants reported moderately higher well-being and showed modestly better cognitive flexibility. Diffusion MRI found a small decrease in axial diffusivity in prefrontal-subcortical white matter, which the authors tentatively interpret as possible structural plasticity. Functional MRI, the stated primary outcome, was largely null.

A single high dose of psilocybin leaves healthy first-time users feeling measurably better a month later, but the search for a matching lasting signature in the brain has come up largely empty. That is the mixed verdict from an imaging study by the Imperial College London psychedelic research group.

The team gave 28 healthy adults, none of whom had ever taken a psychedelic, two capsules four weeks apart. The first held 1 mg of psilocybin, a dose too small to feel. The second held 25 mg, the dose used in depression trials. Volunteers were told only that each capsule could contain anything up to 25 mg. Brain scans were taken before either dose and a month after each, and brain electrical activity was recorded with EEG during the sessions.

The big idea under test was the “entropic brain” hypothesis: that psychedelics work by making brain activity less predictable, and that this temporary loosening is what allows lasting psychological change. On this point the study delivers its clearest result. Within an hour of the 25 mg dose, the EEG signal became markedly more irregular. The people whose brain activity became most irregular reported the most psychological insight the next day and the largest gains in well-being a month on. Statistically, insight appeared to sit in the middle of that chain, as though the altered brain state produced the insight and the insight produced the improvement.

The lasting changes were harder to pin down. Functional MRI, which the authors name as their primary outcome, produced effects they describe as largely weak and non-significant. A measure of how compartmentalized the brain’s networks are, which fell after psilocybin in earlier depression trials, did not differ significantly from placebo here.

The headline-friendly finding is structural. Diffusion imaging showed a small drop in a measure called axial diffusivity in the white-matter tracts linking the prefrontal cortex to the striatum and thalamus. The authors cautiously float this as possible evidence of anatomical neuroplasticity in humans. They also concede that the same signal turns up in axonal injury and in aging, and that their scanning method cannot tell these apart. A second, standard analysis of the same data found nothing.

On the psychological side, well-being rose by about five points on a 56-point scale, and volunteers made fewer errors on a task that tests the ability to abandon an outdated rule.

The caveats are substantial. Every participant got the placebo first and the real dose second, so the effects of time, practice and repeat scanning are tangled up with the drug. All but one called the 25 mg session the most unusual state of consciousness of their life, so blinding was nominal. The analysis plan was not pre-registered, and dozens of comparisons were run on a sample of about 25.

What survives is one well-supported claim and one tentative one. The acute scrambling of brain activity is real and tracks later benefit. Whether one trip physically remodels a healthy human brain remains unanswered.

Actionable Insights

This paper is a mechanistic study in healthy volunteers, not a test of a health intervention, and it measured no aging outcome.

What it does show, in practical terms:

  • Well-being rose 4.7 points more after 25 mg than after placebo at one month, on a scale running from 14 to 70. The UK population average is 51 with a spread (standard deviation) of 9, so this is about half a standard deviation, a moderate effect (Cohen’s d of 0.6). The uncertainty range runs from 0.1 to 9.3 points, so the true benefit could be trivial or large.
  • Cognitive flexibility improved by about 6 percentage points fewer errors on rule-shift trials (d of 0.5), with an uncertainty range that touches zero.
  • The white-matter change was tiny in absolute terms and its meaning is unknown. It should not be read as “brain rejuvenation.”

Context matters. Dosing occurred under medical screening, with psychological preparation, supervision and music. Psilocybin remains a controlled substance in most jurisdictions. The study followed people for one month only and reports no adverse event data in the main text.

Context/Source

  • Open Access Paper: Human brain changes after first psilocybin use
  • Institution: Centre for Psychedelic Research, Imperial College London (lead site and sponsor); corresponding author now at University of California San Francisco
  • Country: United Kingdom (data collection), with co-authors in the USA, Australia and Canada
  • Journal: Nature Communications, volume 17, article 3977, published 5 May 2026
  • Impact Evaluation: The impact score of this journal is 18.1 (Journal Impact Factor, 2025 JCR data year, released June 2026), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

相关阅读:

RapAdmin

Researchers at Sun Yat-sen University report that Bacteroides uniformis, a common gut bacterium depleted in people with cardiovascular disease, protects mice against atherosclerosis by secreting pentadecanoic acid (PA, or C15:0), a 15-carbon saturated fatty acid. PA directly inhibits HMG-CoA reductase, the same enzyme targeted by statins, though roughly 300 times more weakly. Blocking the enzyme lowers cholesterol inside liver cells, which triggers the SREBP2 feedback circuit, raises LDL receptor levels, and clears LDL cholesterol from blood. Plaque burden in treated mice fell by roughly a third to a half. The protection disappeared entirely in mice lacking the liver LDL receptor. In 209 human stool and 211 serum samples, PA was significantly lower in people with dyslipidemia.

For a decade, pentadecanoic acid has had one job in nutrition science: it was the molecule you measured in someone’s blood to estimate how much dairy fat they ate. Because cows and other ruminants make it and humans were assumed not to, C15:0 in serum was treated as a reasonably objective dietary biomarker, more trustworthy than a food questionnaire. Epidemiologists used it to show, repeatedly and somewhat awkwardly for dietary guidelines, that people with more dairy fat in their blood had less cardiovascular disease.

The big idea in this paper is that the biomarker was never purely dietary. Gut bacteria make it too, in quantities large enough to matter, and the molecule itself appears to do the work.

The team started from human metagenomes, comparing 223 patients with atherosclerotic cardiovascular disease against 189 healthy controls, and found Bacteroides species depleted in the patients. Feeding live B. uniformis to atherosclerosis-prone mice cut plaque and dropped LDL cholesterol. Heat-killed bacteria did nothing, which pointed to a secreted molecule rather than a structural component of the cell. So they grew 27 liters of the bacterium, split the broth across solvents, and tracked LDL uptake in liver cells through round after round of fractionation until 51.6 milligrams of a single pure compound remained. Mass spectrometry and NMR identified it as PA.

Then comes the part that makes the story mechanistic rather than correlative. Purified human HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis, binds PA directly. Three independent methods agree on the affinity, landing between 6 and 7 micromolar. Enzyme kinetics show the fatty acid competes with the natural substrate for the same site. Giving PA alone to mice reproduced most of the bacterium’s benefit. Deleting either of two bacterial genes needed to make PA stripped most of the protection away. And knocking out the LDL receptor in mouse liver abolished it completely, which ties the whole chain together: bacterium makes fatty acid, fatty acid blocks the enzyme, liver senses the cholesterol shortfall, liver puts out more LDL receptors, LDL leaves the blood.

Screening 100 gut strains showed PA production is largely confined to the Bacteroidota phylum, and the biosynthetic genes turn up across more than 4,700 reference genomes. In the authors’ own clinical samples, people with dyslipidemia had less PA in both stool and serum.

The honest reading is that this reframes an epidemiological puzzle rather than solving a clinical problem. If much of the C15:0 in blood is microbial rather than dietary, then twenty years of dairy-fat biomarker studies have been partly measuring the microbiome. That is a real contribution. Whether swallowing C15:0 does anything useful in a human artery is a separate question this paper does not answer.

Actionable Insights

The effect sizes here are large but they are mouse effect sizes, and the human data are observational.

In mice given PA alone, aortic plaque fell 57 percent by one measure and 32 percent by another in the same animals. Cohen’s d was 1.87 and 1.36. A d of 1.0 means the average treated animal does better than about 84 percent of controls, so these are strong effects, but the groups still overlap visibly.

The human numbers are far more modest. Across quartiles of serum C15:0 in a 4,150-person Swedish cohort, moving from the bottom quarter to the top quarter tracks with LDL cholesterol lower by 0.3 mmol/L (about 12 mg/dL, a 7.5 percent relative difference) and cardiovascular disease prevalence lower by 2 percentage points, from 10 percent to 8 percent. That is an absolute risk difference implying roughly 50 people would need the higher level for one fewer case, if the association were causal, which is not established. The pooled hazard ratio across 18 studies was 0.75 (95 percent CI 0.61 to 0.93).

Practically: the amount of C15:0 separating the top and bottom quartiles of the population is about 0.09 percent of total fatty acids, a difference achievable through ordinary full-fat dairy intake. Nothing here demonstrates that supplementing beyond that does more, but is something people can try, and then track their results to see if it does help them lower cholesterol (they did not test effects on LP(a)).

Context and Source

  • Paywalled Paper: A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice.
  • Institution: Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, Zhongshan School of Medicine, Sun Yat-sen University (Shenzhen Campus), with the Shenzhen Institute of Advanced Technology (Chinese Academy of Sciences), Shenzhen Bay Laboratory, and the Seventh Affiliated Hospital of Sun Yat-sen University.
  • Country: China.
  • Journal: Nature. Published online 07 October 2026.
  • Impact evaluation: The impact score of this journal is 56.1, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is an Elite impact journal.